11.39
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ROIV Giù?
Forum
Previsione
Precedente Chiudi:
$11.50
Aprire:
$11.58
Volume 24 ore:
1.57M
Relative Volume:
0.26
Capitalizzazione di mercato:
$7.74B
Reddito:
$125.68M
Utile/perdita netta:
$4.81B
Rapporto P/E:
2.0159
EPS:
5.65
Flusso di cassa netto:
$-781.21M
1 W Prestazione:
-0.91%
1M Prestazione:
-0.57%
6M Prestazione:
+2.01%
1 anno Prestazione:
+3.86%
Roivant Sciences Ltd Stock (ROIV) Company Profile
Nome
Roivant Sciences Ltd
Settore
Industria
Telefono
441-295-5950
Indirizzo
7TH FLOOR, 50 BROADWAY, LONDON
Confronta ROIV con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
ROIV
Roivant Sciences Ltd
|
11.38 | 7.72B | 125.68M | 4.81B | -781.21M | 5.65 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
477.85 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
574.13 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
327.25 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
569.71 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.85 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-07-10 | Ripresa | Goldman | Buy |
2024-02-15 | Iniziato | Wolfe Research | Outperform |
2024-01-05 | Iniziato | Piper Sandler | Overweight |
2023-12-12 | Iniziato | Deutsche Bank | Buy |
2023-10-17 | Iniziato | Guggenheim | Buy |
2023-06-08 | Iniziato | BofA Securities | Neutral |
2022-10-27 | Iniziato | JP Morgan | Overweight |
2022-05-23 | Iniziato | SVB Leerink | Outperform |
2022-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
2021-12-15 | Iniziato | Goldman | Buy |
2021-11-08 | Iniziato | H.C. Wainwright | Buy |
2021-10-28 | Iniziato | Citigroup | Buy |
2021-10-26 | Iniziato | Cowen | Outperform |
2021-10-26 | Iniziato | Jefferies | Buy |
2021-10-26 | Iniziato | Truist | Buy |
Mostra tutto
Roivant Sciences Ltd Borsa (ROIV) Ultime notizie
What drives Roivant Sciences Ltd. stock priceExceptional risk-adjusted gains - jammulinksnews.com
What analysts say about Roivant Sciences Ltd. stockTriple-digit profit margins - jammulinksnews.com
Roivant Sciences Ltd. Stock Analysis and ForecastAccelerated wealth building - jammulinksnews.com
Is Roivant Sciences Ltd. a good long term investmentFree Stock Selection - jammulinksnews.com
(ROIV) Investment Analysis and Advice - news.stocktradersdaily.com
Goldman Sachs resumes Roivant Sciences stock coverage with Buy rating By Investing.com - Investing.com South Africa
Goldman Sachs resumes Roivant Sciences stock coverage with Buy rating - Investing.com India
How to Take Advantage of moves in (ROIV) - news.stocktradersdaily.com
Roivant Sciences: Booming Pipeline Without Product Revenues Creates Valuation Riddle - Seeking Alpha
'Just the beginning': Vivek Ramaswamy breaks record in raising fund for Guv election campaign, $8.5 milli - Times of India
Hedge Fund and Insider Trading News: Ken Griffin, Warren Buffett, Michael Burry, AQR Capital Management, Tiger Global Management, Amplify Energy Corp (AMPY), Roivant Sciences ltd (ROIV), and More - Insider Monkey
Roivant Sciences Announces $500M Share Repurchase Program - TipRanks
Roivant Sciences (ROIV): Ramaswamy sells $13 million in shares - Investing.com
HC Wainwright & Co. Reiterates Buy Rating for Roivant Sciences (ROIV) | ROIV Stock News - GuruFocus
Cantor Fitzgerald reiterates overweight rating on Roivant Sciences stock By Investing.com - Investing.com India
H.C. Wainwright reiterates buy rating on Roivant Sciences stock By Investing.com - Investing.com India
Guggenheim maintains buy rating on Roivant Sciences stock amid DM study - Investing.com India
JPMorgan Maintains Positive Outlook on Roivant Sciences (ROIV) | ROIV Stock News - GuruFocus
Roivant (ROIV) Hosts Investor Webinar on Brepocitinib's Role in Dermatomyositis | ROIV Stock News - GuruFocus
Long Term Trading Analysis for (ROIV) - news.stocktradersdaily.com
Roivant (ROIV) Publishes Promising Phase 1 Results for Inhaled M - GuruFocus
Roivant Sciences at Goldman Sachs Conference: Strategic Execution Focus By Investing.com - Investing.com South Africa
Roivant Sciences at Goldman Sachs Conference: Strategic Execution Focus - Investing.com Australia
Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis - Yahoo Finance
Rare Disease Breakthrough: Roivant Reveals Brepocitinib Data for Dermatomyositis Treatment - Stock Titan
Major Shareholder Cashes Out Millions in Roivant Sciences Stock - TipRanks
(ROIV) Trading Advice - news.stocktradersdaily.com
Vivek Ramaswamy’s firm wants to buy biotech companies to bet on bitcoin - MSN
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $324,000 Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) - Defense World
Roivant Sciences Earnings Call: Balancing Growth and Challenges - MSN
Roivant outlines packed 36-month launch and data cycle with under $5B cash reserve and multi-blockbuster pipeline - MSN
Decoding Roivant Sciences Ltd (ROIV): A Strategic SWOT Insight - GuruFocus
Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2024 Earnings Call Transcript - Insider Monkey
Roivant Sciences Full Year 2025 Earnings: EPS Beats Expectations, Revenues Lag - simplywall.st
While Wall Street Naps, These 10 Stocks Run Wild - Insider Monkey
Why Roivant Sciences Ltd. (ROIV) Surged On Thursday - Insider Monkey
Roivant Sciences Ltd (ROIV) Q4 2024 Earnings Call Highlights: Strong Financial Position and ... By GuruFocus - Investing.com Canada
Roivant Sciences Reports Progress and Financial Results - TipRanks
IMVT INVESTIGATION ALERT: Investigation Launched into Private Placement Transaction by Immunovant, Inc. and Attorneys Encourage Investors to Contact Law Firm - The Malaysian Reserve
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Lags Revenue Estimates - MSN
IMVT INVESTIGATION ALERT: Investigation Launched into Private Placement Transaction by Immunovant, Inc. and Attorneys Encourage Investors to Contact Law Firm – Company AnnouncementFT.com - Financial Times
ROIV Crosses Above Key Moving Average Level - Nasdaq
Roivant Sciences earnings missed by $0.03, revenue fell short of estimates - Investing.com South Africa
Roivant Sciences Q4 2025 Earnings Call Transcript - MarketBeat
Roivant Sciences (ROIV) Stock Jumps Nearly 5%: What’s Fueling This Biotech Rally? - Daily Chhattisgarh News
Roivant Sciences Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025 - marketscreener.com
Roivant Sciences Ltd Azioni (ROIV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Roivant Sciences Ltd Azioni (ROIV) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Venker Eric | President & COO |
Jun 20 '25 |
Option Exercise |
3.85 |
100,000 |
385,000 |
1,562,223 |
Venker Eric | President & COO |
Jun 20 '25 |
Sale |
11.45 |
100,000 |
1,145,000 |
1,462,223 |
Ramaswamy Vivek | 10% Owner |
Jun 20 '25 |
Sale |
11.46 |
577,007 |
6,612,500 |
37,284,108 |
Ramaswamy Vivek | 10% Owner |
Jun 18 '25 |
Sale |
11.45 |
565,266 |
6,472,296 |
37,861,115 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):